Incyte

We’re focused on building a portfolio of scientifically differentiated compounds designed to make a meaningful impact for patients. Learn more about von Willebrand disease (VWD), the most common inherited bleeding disorder, and the data presented at this year’s #ISTH2026 Congress. bit.ly/4vuZnQU

Data from our Phase 1/2 multidose study in von Willebrand disease (VWD) was presented at the @isth Congress. Learn more about the data. #ISTH2026 bit.ly/4ydqJ0h

For the first time since acquiring VGA039 (latarcibart), we’re sharing data at the @isth Congress. We look forward to connecting with researchers, clinicians and partners from around the world as we seek to advance care for patients.

Approximately 135,000 people in the U.S. are living with von Willebrand disease (VWD). Learn more about this condition and our commitment to advancing therapies for diseases with significant unmet need. bit.ly/4fj3bzE

Today, we completed our acquisition of Vega Therapeutics, expanding our hematology portfolio into bleeding disorders by adding a differentiated late-stage program for von Willebrand disease (VWD). Read our press release to learn more. bit.ly/4vPMzph

#News: The #CHMP of the @EMA_News has issued a positive opinion for our treatment for moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. Learn more: bit.ly/3SMIHqa

#News: Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Learn more. bit.ly/4fQDdnZ

Pablo Cagnoni reflects on the importance of the new data we shared for our mutCALR-targeted monoclonal antibody in patients with myeloproliferative neoplasms (MPNs) at the @EHA_Hematology Congress. #EHA2026 bit.ly/4awns1W

We shared new positive data for our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) and essential thrombocythemia (ET) at the @EHA_Hematology Congress. Learn more about these data. #EHA2026 bit.ly/4oqcgcQ

We are proud to share Phase 3 data at the @EHA_Hematology Congress, underscoring our commitment to advancing care for patients with diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 bit.ly/4gouMjM

Today, the prestigious Plenary Abstracts Session at the @EHA_Hematology Congress highlighted data from the Phase 3 frontMIND trial for patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 bit.ly/4v45iwN

We're sharing data from our Hematology portfolio at this year's @EHA_Hematology Congress. Check out our press release for more details and stay tuned for updates. #EHA2026 bit.ly/4e5ALc1

We’re looking forward to presenting data from our Hematology portfolio at this year’s @EHA_Hematology Congress! Read our press release to learn more. #EHA2026 bit.ly/4otixVu

Incyte announced an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of @Star_biotech, strengthening our hematology portfolio and expanding our work into bleeding disorders. Read more: bit.ly/4aA7fst

Learn more from Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development, as he discusses the significance of the Phase 3 frontMIND data for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), shared at this year’s @ASCO Meeting. bit.ly/4vc6uhc

Today at the American Society of Clinical Oncology® (@ASCO) Annual Meeting we shared new data from the pivotal frontMIND trial in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL), simultaneously published in @TheLancet. Learn more. #ASCO26 bit.ly/49Pkkhx

Explore data from our oncology portfolio being presented at the American Society of Clinical Oncology® (@ASCO) Annual Meeting. #ASCO26 bit.ly/4dWxgmN

Incyte to present the latest data from our oncology portfolio at the upcoming American Society of Clinical Oncology® (@ASCO) Annual Meeting. Learn more. #ASCO26 bit.ly/4earz5V

Our purpose remains constant: delivering meaningful medicines for patients. Incyte continues to advance with real momentum and a clear plan for long-term growth and innovation. Learn more. bit.ly/4vetZGD

Incyte and @genesismolai are expanding our collaboration designed to accelerate the discovery of potential new medicines. Learn more. bit.ly/4uiY5sl